Company: LIMN
Filing Date: 2025-06-24
Form Type: S-1
Source: 0001410578-25-001432
Chunk: 281

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-24
Form: S-1
Chunk 281
---
 their over-allotment option, at a purchase price of $ 10.00per Unit, generating gross proceeds of $ 276,000,000. Each Unit consists of oneshare of Class A common stock, and one-fourth of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase oneshare of Class A common stock at a price of $ 11.50per share, subject to adjustment. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. The warrants will become exercisable on the later of 30 daysafter the completion of the initial Business Combination or 12 monthsfrom the closing of the IPO, March 9, 2021, and will expire five yearsafter the completion of the initial Business Combination, or earlier upon redemption or liquidation (see Note 8). The Company paid an underwriting fee at the closing of the IPO of $ 5,520,000 . As of March 9, 2021, an additional fee of $ 9,660,000 (see Note 7) was deferred and will become payable upon the Company’s completion of an initial Business Combination. The deferred portion of the fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event the Company completes its initial Business Combination. All of the 27,600,000 shares of Class A common stock sold as part of the units in the IPO contain a redemption feature which allows for the redemption of such shares of Class A common stock in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. The Class A common stock is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately